[go: up one dir, main page]

CY1117883T1 - Φαρμακευτικες συνθεσεις διπλης δρασης με βαση υπερδομες απο ανταγωνιστη/αποκλειστη υποδοχεα αγγειοτενσινης (arb) και αναστολεα ουδετερης ενδοπεπτιδασης (nep) - Google Patents

Φαρμακευτικες συνθεσεις διπλης δρασης με βαση υπερδομες απο ανταγωνιστη/αποκλειστη υποδοχεα αγγειοτενσινης (arb) και αναστολεα ουδετερης ενδοπεπτιδασης (nep)

Info

Publication number
CY1117883T1
CY1117883T1 CY20161100778T CY161100778T CY1117883T1 CY 1117883 T1 CY1117883 T1 CY 1117883T1 CY 20161100778 T CY20161100778 T CY 20161100778T CY 161100778 T CY161100778 T CY 161100778T CY 1117883 T1 CY1117883 T1 CY 1117883T1
Authority
CY
Cyprus
Prior art keywords
arb
risk
container
double
component
Prior art date
Application number
CY20161100778T
Other languages
English (en)
Inventor
Suliman Al-Fayoumi
Jiahui Hu
Natrajan Kumaraperumal
Alan Edward Royce
Colleen Ruegger
Erika Aina Zannou
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40451030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117883(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1117883T1 publication Critical patent/CY1117883T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Στερεές μορφές δοσολογίας από του στόματος, ιδιαίτερα δισκία, μιας φαρμακευτικής σύνθεσης που περιέχει ένα υπερμοριακό σύμπλοκο μπορούν να παρασκευαστούν από μια διαδικασία άμεσης συμπίεσης ή μια διαδικασία συμπίεσης όπως είναι η συμπίεσης ελάστρου. Τέτοιες στερεές μορφές δοσολογίας από του στόματος χαρακτηρίζονται από ένα προφίλ άμεσης απελευθέρωσης που επιτρέπει ταχεία αποδέσμευση του θεραπευτικού παράγοντα. Ένα ιδιαίτερα χρήσιμο υπερ-μοριακό σύμπλοκο είναι το τρινάτριο [3-((1S,3R)-1-διφαινυλ-4-υλομεθυλ- 3- αιθοξυκαρβονυλο- 1- βουτυλκαρβαμοϋλο) προπιονικό-(S) -3'-μεθυλο-2' (πεντανυλο {2"-(τετραζολ-5-υλικό) διφαινυλ-4'-υλο-μεθυλ}αμινο)βουτυρικός]ημιπενταϋδρίτης.
CY20161100778T 2007-11-06 2016-08-08 Φαρμακευτικες συνθεσεις διπλης δρασης με βαση υπερδομες απο ανταγωνιστη/αποκλειστη υποδοχεα αγγειοτενσινης (arb) και αναστολεα ουδετερης ενδοπεπτιδασης (nep) CY1117883T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98566807P 2007-11-06 2007-11-06
EP08848154.4A EP2217205B1 (en) 2007-11-06 2008-11-04 Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor

Publications (1)

Publication Number Publication Date
CY1117883T1 true CY1117883T1 (el) 2017-05-17

Family

ID=40451030

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20151100426T CY1116280T1 (el) 2007-11-06 2015-05-14 Φαρμακευτικες συνθεσεις διπλης δρασης με βαση υπερδομες απο ανταγωνιστη/αποκλειστη υποδοχεα αγγειοτενσινης (arb) και αναστολεα ουδετερης ενδοπεπτιδασης (νερ)
CY20161100778T CY1117883T1 (el) 2007-11-06 2016-08-08 Φαρμακευτικες συνθεσεις διπλης δρασης με βαση υπερδομες απο ανταγωνιστη/αποκλειστη υποδοχεα αγγειοτενσινης (arb) και αναστολεα ουδετερης ενδοπεπτιδασης (nep)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20151100426T CY1116280T1 (el) 2007-11-06 2015-05-14 Φαρμακευτικες συνθεσεις διπλης δρασης με βαση υπερδομες απο ανταγωνιστη/αποκλειστη υποδοχεα αγγειοτενσινης (arb) και αναστολεα ουδετερης ενδοπεπτιδασης (νερ)

Country Status (33)

Country Link
US (3) US20100267786A1 (el)
EP (4) EP4186491A1 (el)
JP (2) JP5653218B2 (el)
KR (2) KR101700062B1 (el)
CN (2) CN103251587A (el)
AR (1) AR069184A1 (el)
AU (1) AU2008324878B2 (el)
BR (1) BRPI0823505A2 (el)
CA (1) CA2703598C (el)
CL (1) CL2008003298A1 (el)
CY (2) CY1116280T1 (el)
DK (3) DK2295035T3 (el)
EC (1) ECSP10010160A (el)
ES (3) ES2587336T3 (el)
FI (1) FI3067043T3 (el)
GT (1) GT201000131A (el)
HR (3) HRP20150459T1 (el)
HU (2) HUE061321T2 (el)
IL (3) IL262990B2 (el)
JO (1) JOP20080499B1 (el)
MA (1) MA31797B1 (el)
MX (1) MX2010004930A (el)
MY (1) MY153730A (el)
NZ (1) NZ584686A (el)
PE (2) PE20091390A1 (el)
PL (3) PL2217205T3 (el)
PT (3) PT2217205E (el)
RU (1) RU2493844C3 (el)
SG (1) SG185951A1 (el)
SI (3) SI2217205T1 (el)
TN (1) TN2010000200A1 (el)
TW (1) TWI484982B (el)
WO (1) WO2009061713A1 (el)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010004930A (es) 2007-11-06 2010-05-27 Novartis Ag Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep).
MA33364B1 (fr) 2009-05-28 2012-06-01 Novartis Ag Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
MX2011012628A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
CN103079554A (zh) * 2010-08-24 2013-05-01 诺华有限公司 在接受抗凝血剂疗法的哺乳动物中治疗高血压和/或预防或治疗心力衰竭
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
CA2882771C (en) 2012-08-24 2021-02-23 Novartis Ag Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
AU2014216417B2 (en) 2013-02-14 2016-05-12 Novartis Ag Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy
HRP20180958T1 (hr) 2013-02-14 2018-07-27 Novartis Ag Supstituirani derivati bisfenolbutanfosfonske kiseline kao inhibitori za nep (neutralnu endopeptidazu)
RS59816B1 (sr) 2013-08-26 2020-02-28 Novartis Ag Nova primena
WO2015030711A1 (en) 2013-08-26 2015-03-05 Novartis Ag New use
CN106795099B (zh) * 2014-04-10 2019-11-26 南京奥昭生物科技有限公司 用于治疗高血压和心血管疾病的前药和组合物
CN105461647B (zh) * 2014-09-28 2018-06-29 四川海思科制药有限公司 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途
CA2970192C (en) 2014-12-08 2020-08-04 Crystal Pharmatech Co., Ltd. Crystalline forms of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof
CN104473938B (zh) * 2014-12-30 2017-06-09 北京瑞都医药科技有限公司 一种治疗慢性心衰药物及其制备方法
CN104826115A (zh) * 2015-04-19 2015-08-12 浙江巨泰药业有限公司 一种抗心衰药物组合物及其制备方法
HUE062195T2 (hu) 2015-05-11 2023-10-28 Novartis Ag Szakubitril - valzartán adagolási rend szívelégtelenség kezelésére
JP2018516267A (ja) 2015-05-29 2018-06-21 ノバルティス アーゲー 代謝性疾患を治療するためのサクビトリルおよびバルサルタン
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
CN105997993B (zh) * 2015-07-11 2018-03-30 麦丽芳 一种用于心血管疾病治疗的固体口服型制剂及其制备方法
CN106176723A (zh) * 2015-07-11 2016-12-07 凌莉 一种固体药物组合物及其制备方法
CN106176725A (zh) * 2015-07-11 2016-12-07 凌莉 一种提高稳定性的药物组合物及其制备方法和用途
CN105997994A (zh) * 2015-07-11 2016-10-12 凌莉 一种固体口服型制剂及其制备方法
CN106074421A (zh) * 2015-07-11 2016-11-09 凌莉 一种提高稳定性的药物组合物
CN106176724A (zh) * 2015-07-11 2016-12-07 凌莉 一种稳定的固体药物组合物及其制备方法
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2017020841A1 (zh) * 2015-08-03 2017-02-09 深圳信立泰药业股份有限公司 一种含有lcz696的药物组合物及其制备方法
WO2017037596A1 (en) * 2015-08-28 2017-03-09 Dr. Reddy's Laboratories Limited Amorphous solid dispersion of lcz-696
EP3355880A1 (en) 2015-08-28 2018-08-08 Novartis AG New use
CN106580908A (zh) * 2015-10-16 2017-04-26 深圳信立泰药业股份有限公司 一种用于心血管疾病治疗的口服制剂及其制备方法
CN105669581B (zh) * 2015-11-09 2017-03-22 成都苑东生物制药股份有限公司 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物
WO2017085573A1 (en) * 2015-11-20 2017-05-26 Lupin Limited Amorphous sacubitril-valsartan complex and process for preparation thereof
CN105330609B (zh) * 2015-12-07 2017-12-22 南京正大天晴制药有限公司 一种制备lcz696的方法
CN105929031B (zh) * 2015-12-18 2018-08-21 重庆两江药物研发中心有限公司 一种血管紧张素受体拮抗剂和nep抑制剂的复合物中杂质的分离方法
CN105935358B (zh) * 2015-12-18 2019-06-07 重庆两江药物研发中心有限公司 一种沙库比曲缬沙坦缓释剂及其制备方法
CN106905253B (zh) * 2015-12-23 2020-01-03 正大天晴药业集团股份有限公司 一种超分子复合物的结晶
WO2017134597A1 (en) * 2016-02-03 2017-08-10 Novartis Ag Galenic formulations of organic compounds
HK1256865A1 (zh) 2016-02-03 2019-10-04 Novartis Ag 有机化合物的盖伦制剂
CN105748420B (zh) * 2016-03-04 2018-11-06 山东省药学科学院 一种治疗心力衰竭的lcz696缓释骨架片的制备方法
CN105902506A (zh) * 2016-06-12 2016-08-31 佛山市腾瑞医药科技有限公司 一种沙卡布曲缬沙坦制剂及其应用
WO2018069937A1 (en) 2016-10-13 2018-04-19 Mylan Laboratories Limited Solid dispersions of trisodium sacubitril valsartan and process for the preparation thereof
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
ES2890573T3 (es) * 2017-03-31 2022-01-20 Tiefenbacher Alfred E Gmbh & Co Kg Producto extruido de fusión en caliente estable que contiene valsartán y sacubitrilo
WO2018211479A1 (en) * 2017-05-19 2018-11-22 Lupin Limited Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
WO2019020706A1 (en) 2017-07-28 2019-01-31 Synthon B.V. PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN
EP3694493A1 (en) 2017-10-13 2020-08-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Tablet containing valsartan and sacubitril
WO2019180735A1 (en) * 2018-03-19 2019-09-26 Natco Pharma Limited Stable pharmaceutical compositions comprising sacubitril-valsartan complex
US11877576B2 (en) 2018-06-22 2024-01-23 Ideaz, Llc Diphenyl tablets and methods of preparing the same
KR20210032437A (ko) 2018-08-23 2021-03-24 노파르티스 아게 심부전의 치료를 위한 신규한 약제학적 용도
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
EP3766484B1 (en) 2019-07-19 2021-08-25 Zentiva, K.S. Solid pharmaceutical dosage form comprising valsartan and sacubitril
KR102545274B1 (ko) 2020-02-26 2023-06-20 에리슨제약(주) 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법
KR20210120560A (ko) 2020-03-27 2021-10-07 주식회사 유영제약 고함량의 주성분을 포함하는 정제 및 그 제조방법
KR20210138510A (ko) 2020-05-12 2021-11-19 에리슨제약(주) 사쿠비트릴, 발사르탄 및 네비보롤을 포함하는 심부전 및 허혈성 심질환의 예방 또는 치료용 약제학적 조성물 및 이를 포함하는 약제학적 복합제제
KR20220091767A (ko) 2020-12-24 2022-07-01 주식회사 보령 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
KR102486815B1 (ko) 2021-01-20 2023-01-10 주식회사 대웅제약 Nep 저해제 및 arb를 포함하는 약학 조성물 및 이의 제조 방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US607893A (en) 1898-07-26 Automatic switch-operating machine
US607355A (en) 1898-07-12 Carrier for bicycles
US608220A (en) 1898-08-02 Mechanical movement
US735093A (en) 1903-01-31 1903-08-04 Oscar Greenwald Elevator-cable guard.
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
BR9814877A (pt) * 1997-11-17 2000-10-03 Smithkline Beecham Corp Formulações de dosagem oral de elevada carga medicamentosa de liberação imediata e modificada e processos para sua fabricação
US6248729B1 (en) * 1998-06-17 2001-06-19 Bristol-Myers Squibb Co. Combination of an ADP-receptor blocking antiplatelet drug and antihypertensive drug and a method for preventing a cerebral infarction employing such combination
CZ297795B6 (cs) * 1998-12-23 2007-03-28 Novartis Ag Tablety obsahující valsartan
PE20020613A1 (es) 2000-07-19 2002-08-07 Novartis Ag Sales de (s)-n-(1-carboxi-2-metil-prop-1-il)-n-pentanoil-n-[2'-(1h-tetrazol-5-il)-bifenil-4-ilmetil]-amina como antagonista del receptor at1
KR20100057704A (ko) * 2002-01-17 2010-05-31 노파르티스 아게 발사르탄 및 ｎｅｐ 저해제를 포함하는 제약학적 조성물
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
JP3751287B2 (ja) * 2002-03-27 2006-03-01 バイエル薬品株式会社 小型化されたニフェジピン有核錠剤
AU2003223637A1 (en) 2002-04-15 2003-11-03 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan)
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
EP1511739B1 (en) 2003-03-17 2008-04-30 Teva Pharmaceutical Industries Ltd. Polymorphs of valsartan
JP2009513543A (ja) * 2003-07-16 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング クロルタリドンの組み合わせ
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
AU2006307470A1 (en) * 2005-10-27 2007-05-03 Lupin Limited Pharmaceutical formulation of losartan
US20080227836A1 (en) 2005-10-31 2008-09-18 Lupin Ltd Stable Solid Oral Dosage Forms of Valsartan
EP2260755B1 (en) 2005-11-07 2013-12-25 Stryker Corporation Patient handling device including normal condition lamp
AU2006311723A1 (en) 2005-11-08 2007-05-18 Novartis Ag Combination of an angiotensin II receptor blocker, a calcium channel blocker and another active agent
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
MX2010004930A (es) 2007-11-06 2010-05-27 Novartis Ag Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep).

Also Published As

Publication number Publication date
MY153730A (en) 2015-03-13
EP2295035A2 (en) 2011-03-16
HRP20150459T1 (hr) 2015-07-17
KR20150139624A (ko) 2015-12-11
FI3067043T3 (fi) 2023-03-18
CN103251587A (zh) 2013-08-21
KR101700062B1 (ko) 2017-01-26
US20210085631A1 (en) 2021-03-25
EP2295035B1 (en) 2016-05-18
JP2015038069A (ja) 2015-02-26
CA2703598A1 (en) 2009-05-14
EP2217205B1 (en) 2015-03-04
HK1143529A1 (en) 2011-01-07
JOP20080499B1 (ar) 2022-09-15
JP5653218B2 (ja) 2015-01-14
GT201000131A (es) 2012-04-30
EP2217205A1 (en) 2010-08-18
AU2008324878A1 (en) 2009-05-14
KR20100085087A (ko) 2010-07-28
ES2587336T3 (es) 2016-10-24
PL3067043T3 (pl) 2023-05-08
IL249922A0 (en) 2017-03-30
KR101700062B9 (ko) 2022-11-23
CN101848700A (zh) 2010-09-29
SI3067043T1 (sl) 2023-04-28
NZ584686A (en) 2013-03-28
PE20141072A1 (es) 2014-09-10
MX2010004930A (es) 2010-05-27
US20100267786A1 (en) 2010-10-21
ECSP10010160A (es) 2010-06-29
AR069184A1 (es) 2010-01-06
ES2939163T3 (es) 2023-04-19
IL262990B1 (en) 2023-06-01
DK3067043T3 (da) 2023-02-27
JP2011503082A (ja) 2011-01-27
IL262990A (en) 2018-12-31
RU2493844C3 (ru) 2017-07-05
US20240115536A1 (en) 2024-04-11
CY1116280T1 (el) 2017-03-15
EP2295035A3 (en) 2012-08-08
ES2536514T3 (es) 2015-05-26
RU2010123027A (ru) 2011-12-20
IL205208A (en) 2017-01-31
RU2493844C2 (ru) 2013-09-27
HUE061321T2 (hu) 2023-06-28
HRP20230178T3 (hr) 2023-03-31
TN2010000200A1 (en) 2011-11-11
BRPI0823505A2 (pt) 2015-06-16
HK1149721A1 (en) 2011-10-14
HUE028866T2 (en) 2017-01-30
IL262990B2 (en) 2023-10-01
WO2009061713A1 (en) 2009-05-14
EP3067043A1 (en) 2016-09-14
HK1224195A1 (en) 2017-08-18
EP3067043B1 (en) 2022-11-30
PL2295035T3 (pl) 2016-11-30
PT3067043T (pt) 2023-03-01
PT2217205E (pt) 2015-06-08
EP4186491A1 (en) 2023-05-31
IL205208A0 (en) 2010-12-30
PE20091390A1 (es) 2009-10-13
DK2217205T3 (en) 2015-05-11
SG185951A1 (en) 2012-12-28
AU2008324878B2 (en) 2013-04-18
TW200936183A (en) 2009-09-01
SI2217205T1 (sl) 2015-10-30
SI2295035T1 (sl) 2016-09-30
MA31797B1 (fr) 2010-10-01
PL2217205T3 (pl) 2015-07-31
KR101589317B9 (ko) 2022-11-23
DK2295035T3 (en) 2016-08-29
CA2703598C (en) 2016-08-09
PT2295035T (pt) 2016-08-22
HRP20160988T1 (hr) 2016-10-07
TWI484982B (zh) 2015-05-21
CL2008003298A1 (es) 2009-06-26
KR101589317B1 (ko) 2016-01-28

Similar Documents

Publication Publication Date Title
CY1117883T1 (el) Φαρμακευτικες συνθεσεις διπλης δρασης με βαση υπερδομες απο ανταγωνιστη/αποκλειστη υποδοχεα αγγειοτενσινης (arb) και αναστολεα ουδετερης ενδοπεπτιδασης (nep)
CY1114566T1 (el) Δοσολογικη μορφη πραμιπεξολης χορηγουμενη μια φορα την ημερα
CY1117895T1 (el) Στερεα φαρμακευτικα σκευασματα που περιεχουν bibw 2992
MX2009001711A (es) Formulaciones de liberacion sostenida de topiramato.
NO20084256L (no) DPP IV inhibitorformuleringer
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
CY1108973T1 (el) Ξηρα κοκκοποιημενη συνθεση η οποια περιλαμβανει εμτρισιταβινη και τενοφοβιρη df
TNSN08326A1 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
HUS1600021I1 (hu) MEK inhibitorok és módszerek azok felhasználására
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
GT200600258A (es) Derivados de n-(piridin-2-il)-sulfonamida
UA116334C2 (uk) Тверді форми дозування бендамустину
TW200637874A (en) Peptides with neuropeptide-2 receptor (Y2R) agonist activity
CY1118180T1 (el) Μεθοδος για παρασκευη στερεας φαρμακευτικης συνθεσης
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции
NO20074933L (no) Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
TW200806311A (en) Neuropeptide-2 receptor-agonists
CY1109405T1 (el) Στοματο-διασπειρομενα δισκια δομπεριδονης
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
BRPI0817275A2 (pt) Combinação farmacêutica de alisquireno e valsartana
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
WO2009032843A3 (en) Deuterated ethambutols and their use
TR200200310T2 (tr) Interlökin-5 inhibe eden 6-azaurasil türevleri.